News and Media

News and Media

  • Valerio Therapeutics announces a capital reduction motivated by losses by reducing the nominal value of the Company’s shares

    February 6, 2024

  • Half-year liquidity contract statement for Valerio Therapeutics

    January 25, 2024

  • Valerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities (English)

    New identity unveiled, with the aim at developing innovative therapies […]

    September 28, 2023

  • Onxeo changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023 (English)

    All the resolutions approved by the Board of Directors were […]

    June 6, 2023

  • Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures (English)

    May 16, 2023

  • Publication of the 2022 Annual Financial Report

    April 28, 2023

  • Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates

    April 24, 2023

  • Onxeo will publish its full-year results on April 24, 2023

    April 21, 2023

  • Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures

    March 16, 2023

Press Release Signup

Subscribe to receive our Press Releases when they come out.

Press Releases

  • Shareholder’s Meeting

    June 1

  • Corporate Presentation – Q2 2023
  • Corporate Presentation 4Q 2023